Department of Obstetrics and Gynecology, Private Ada Hospital, 28100 Giresun, Turkey.
Department of Gynecological Oncology, Niger Turkey Friendship Hospital, Niamey G3PR+2JJ, Niger.
Medicina (Kaunas). 2024 Sep 19;60(9):1530. doi: 10.3390/medicina60091530.
: The purpose of this study is to evaluate the impact of maternal ischemia-modified albumin (IMA) levels on pregnancy-related complications, fetal growth, and development over time. : The prospective longitudinal and single-center study included 43 pregnant women ages 18 to 43. Routine pregnancy follow-up began at the first antenatal examination for all pregnant women before 14 weeks gestation, with IMA levels measured during the first, second, and third trimesters. The albumin cobalt binding test was used to determine the amount of ischemia-modified albumin (IMA). The patients' medical, sociodemographic, and nutritional data were analyzed. The primary outcome was to investigate how changes in maternal ischemia affected albumin levels during pregnancy and the relationship between these changes and newborn weight. : This study included 43 cases with a mean age of 28.5 ± 5.2 years and a mean gestation period of 39.2 ± 1.3 weeks. The mean IMA levels for cases in the first trimester, second trimester, and third trimester were 0.53 ± 0.06, 0.64 ± 0.11, and 0.64 ± 0.06, respectively. The second and third trimesters showed significantly higher levels of ischemia-modified albumin (IMA) than the first trimester ( < 0.01). There was no statistically significant difference in IMA levels between the second and third trimesters ( = 1.000; > 0.05). There was no statistically significant correlation between fetal birth and percentage changes in IMA measurements between the first and second trimesters, the first and third trimesters, or the second and third trimesters ( > 0.05). : Our study determined that maternal ischemia-modified albumin levels during pregnancy did not correlate with fetal birth weight. Our findings revealed that age, sociodemographic changes, BMI, weight gain, and pregnancy complications had no effect on the change in IMA levels during pregnancy. We believe that this result will serve as a benchmark for future studies on IMA levels during pregnancy.
本研究旨在评估母体缺血修饰白蛋白（IMA）水平对妊娠相关并发症、胎儿生长和发育的影响。
这项前瞻性纵向单中心研究纳入了 43 名年龄在 18 至 43 岁的孕妇。所有孕妇在 14 周妊娠前进行首次产前检查，在妊娠第 1、2 和 3 个月末测量 IMA 水平。采用白蛋白钴结合试验测定缺血修饰白蛋白（IMA）的含量。分析患者的医疗、社会人口学和营养数据。主要结局是研究母体 IMA 变化如何影响妊娠期间白蛋白水平，以及这些变化与新生儿体重的关系。
本研究共纳入 43 例，平均年龄 28.5 ± 5.2 岁，平均孕龄 39.2 ± 1.3 周。妊娠第 1、2 和 3 个月末病例的 IMA 水平分别为 0.53 ± 0.06、0.64 ± 0.11 和 0.64 ± 0.06。第 2 和第 3 个月末的缺血修饰白蛋白（IMA）水平明显高于第 1 个月末（<0.01）。第 2 个和第 3 个月末的 IMA 水平差异无统计学意义（=1.000；>0.05）。第 1 个和第 2 个月末、第 1 个和第 3 个月末以及第 2 个和第 3 个月末之间 IMA 测量的胎儿出生和百分比变化之间无统计学显著相关性（>0.05）。
我们的研究表明，妊娠期间母体 IMA 水平与胎儿出生体重无关。我们的研究结果表明，年龄、社会人口学变化、BMI、体重增加和妊娠并发症对 IMA 水平在妊娠期间的变化没有影响。我们相信，这一结果将为未来关于妊娠期间 IMA 水平的研究提供基准。
